Imagine Pharma is committed to expanding and building its pipeline of programs across each of its platforms. These programs address multiple disease states and unmet needs in large underserved markets.
Descriptions of our existing programs by platform can be found below.
The first of its kind, PT-1 EPO is the oral form of Epogen, a well-established drug for the treatment of anemia in patients with renal failure, undergoing chemotherapy and other causes.
| Discovery | Pre-Clinical | Phase 1 |
|---|---|---|
Oral form of octreotide for the treatment of carcinoid tumors and debilitating symptoms of carcinoid syndrome
| Discovery | Pre-Clinical | Phase 1 |
|---|---|---|
Oral form of GLP-1 agonist used for the treatment of type 2 diabetes
| Discovery | Pre-Clinical | Phase 1 |
|---|---|---|
Top-1 therapy can accelerate the re-epithelialization and healing of partial thickness skin donor sites which can reduce pain and time to healing.
| Discovery | Pre-Clinical | Phase 1 |
|---|---|---|
Top-2 can accelerate the healing of diabetic wounds by expediting re-epithelialization, skin regeneration, and collagen deposition.
| Discovery | Pre-Clinical | Phase 1 |
|---|---|---|
Top-3 therapy can accelerate the re-epithelialization and healing of second degree burn sites which can reduce pain and time to healing.
| Discovery | Pre-Clinical | Phase 1 |
|---|---|---|
Limitless numbers of insulin-producing islet cells can be generated from a single pancreas by Imagine Pharma’s innovative growth factors and technique. These islet cells can be transplanted (IV) into type 1 diabetic patients as a cure for their disease.
| Discovery | Pre-Clinical | Phase 1 |
|---|---|---|
Imagine Pharma can isolate and propagate insulin producing islet cells from biopsies of type 1 diabetic pancreases. This revolution in islet isolation and propagation allows the generation and propagation of Beta cells from T1D patients and the autologous islet transplantation to cure type 1 diabetes.
| Discovery | Pre-Clinical | Phase 1 |
|---|---|---|
| Key | 2021-2023 | 2023-2024 |
|---|
The foundation of the three platforms forms the basis of a multi-year scientific inquiry which will lead to many discoveries and potential therapies to increase the number of patients that can benefit from our transformative first-in-class treatments. With research programs targeting areas where there are currently no treatments and current approaches are not cost effective or have failed, Imagine is pushing the boundaries of what is possible.
We are actively seeking partnerships for the development of complementary therapeutic approaches to explore a broader set of indications and reach more patients.
| R & D Engine | Discovery | Pre-Clinical | Phase 1 |
|---|---|---|---|
| 2nd Generation Oral Delivery System | |||
| Additional Oral Biologics | |||
| Comprehensive Lung Healing Initiative | |||
| Comprehensive Bowel Initiative | |||
| Personalized Blood Vessel |
|||
If there are important updates to our pipeline or research, you can be the first to hear about them.
Read the latest news, announcements, and more in the Imagine Pharma newsroom.
Our team has decades of drug discovery and development experience in the industry and are working to bring to market transformative first-in-class treatments.
Get to know the team committed to developing innovative treatments for patients.